Aurobindo Pharma Ltd (AUROPHARMA) AI Stock Analysis

• Market Cap: ₹607.11B
• Dividend Yield: 0.39%
• Average Volume (3M): 41.91K
• Price to Earnings (P/E): 17.9
• Beta (1Y): 1.05
• Revenue Growth: 7.76%
• EPS Growth: -2.84%
• Country: IN
• Employees: 26,015
• Sector: Healthcare
• Sector Strength: 47
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 14.20
• Shares Outstanding: 580,801,640
• 10 Day Avg. Volume: 60,060
• 30 Day Avg. Volume: 41,913
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,215.17
• Price Target Upside: 18.13% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 71 Outperform
• Price Target: ₹1,261.00 ▲(22.59% Upside)

Aurobindo Pharma's overall score is driven by strong financial performance, characterized by robust revenue growth and improved profitability, supported by solid cash flow management. The stock's valuation is reasonable, but technical indicators suggest neutral market momentum, reflecting mixed investor sentiment.

Aurobindo Pharma Ltd Business Overview & Revenue Model

Company Description

Aurobindo Pharma Ltd (AUROPHARMA) is a leading global pharmaceutical company headquartered in India, engaged in the research, development, manufacturing, and marketing of a wide range of generic pharmaceuticals and active pharmaceutical ingredients (APIs). The company's product portfolio spans anti-infectives, cardiovascular, central nervous system, gastroenterology, anti-diabetics, and anti-allergics, among others. Aurobindo Pharma operates in both regulated and non-regulated markets, with a significant presence in the United States, Europe, and other key emerging markets.

How the Company Makes Money

Aurobindo Pharma Ltd generates revenue primarily through the sale of generic pharmaceuticals and active pharmaceutical ingredients (APIs). The company's revenue streams are diversified across multiple therapeutic categories, with a significant portion of its income derived from its operations in the highly regulated markets of the United States and Europe. Aurobindo Pharma benefits from its vertically integrated business model, which allows the company to control the entire supply chain from API manufacturing to finished dosage forms. This integration not only enhances cost efficiency but also ensures consistent quality and supply reliability. The company actively pursues strategic partnerships and alliances to expand its market reach and product offerings. Additionally, Aurobindo invests in research and development to introduce new generic products and enhance its existing portfolio, thereby maintaining competitive advantage and driving future growth.

Aurobindo Pharma Ltd Financial Statement Overview

Summary

Aurobindo Pharma demonstrates strong financial health with impressive revenue growth, improved profitability margins, and a robust balance sheet with low leverage. Cash flow performance has significantly recovered, indicating effective cash management and positioning the company well for future growth.

Income Statement

Aurobindo Pharma has demonstrated strong revenue growth with a significant increase from ₹290,018.7 million to ₹317,237.3 million, indicating robust sales momentum. Gross profit margin has improved to 58.9%, and net profit margin has steadily grown to 11%. This highlights the company's enhanced profitability. However, EBITDA margin has decreased slightly, suggesting some pressure on operating efficiency.

Balance Sheet

The balance sheet reflects a solid financial position with a low debt-to-equity ratio of 0.25, showcasing effective leverage management. The equity ratio stands at 65.6%, indicating a strong equity base relative to total assets. Return on equity is satisfactory at 10.7%, though it suggests potential room for improvement in generating shareholder returns.

Cash Flow

The cash flow statement reveals a strong recovery in free cash flow, which turned positive at ₹19,567.6 million from a negative position the previous year. Operating cash flow has increased significantly, leading to a favorable operating cash flow to net income ratio. The free cash flow to net income ratio has also improved, reflecting better cash management and profitability.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2022	Dec 2022	Dec 2021
Income Statement
Total Revenue	314.88B	317.24B	290.02B	233.67B	246.17B	247.75B
Gross Profit	184.62B	186.97B	160.16B	69.38B	129.75B	80.49B
EBITDA	70.40B	66.05B	61.79B	45.36B	40.09B	85.29B
Net Income	34.86B	34.86B	31.73B	26.48B	19.27B	53.35B
Balance Sheet
Total Assets	497.85B	497.85B	450.72B	339.22B	398.90B	338.54B
Cash, Cash Equivalents and Short-Term Investments	82.36B	82.36B	63.25B	45.58B	62.24B	56.21B
Total Debt	82.63B	82.63B	66.48B	32.79B	52.86B	53.39B
Total Liabilities	171.38B	171.38B	152.21B	93.48B	130.38B	119.25B
Stockholders Equity	326.53B	326.53B	298.43B	245.76B	268.40B	219.30B
Cash Flow
Free Cash Flow	0.00	19.57B	-11.27B	23.12B	-3.34B	14.55B
Operating Cash Flow	0.00	39.25B	24.35B	50.16B	23.87B	33.29B
Investing Cash Flow	0.00	-18.76B	-45.37B	-32.12B	-39.78B	5.99B
Financing Cash Flow	0.00	1.20B	8.00B	-29.69B	18.14B	-13.65B

Aurobindo Pharma Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1028.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AUROPHARMA, the sentiment is Negative. The current price of 1028.65 is below the 20-day moving average (MA) of 1071.63, below the 50-day MA of 1105.56, and below the 200-day MA of 1166.69, indicating a bearish trend. The MACD of -19.34 indicates Positive momentum. The RSI at 36.44 is Neutral, neither overbought nor oversold. The STOCH value of 23.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:AUROPHARMA.

Aurobindo Pharma Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALKEM	72 Outperform	₹647.71B	28.35		0.84%	4.49%	11.22%
LUPIN	72 Outperform	₹878.69B	23.73		0.63%	12.40%	63.16%
ZYDUSLIFE	72 Outperform	₹993.71B	21.73		1.13%	14.52%	9.46%
AUROPHARMA	71 Outperform	₹607.11B	17.90		0.39%	7.76%	-2.84%
GLENMARK	62 Neutral	₹550.97B	73.11		0.13%	10.99%	―
LAURUSLABS	54 Neutral	₹468.76B	92.06		0.14%	17.31%	242.99%
Sector *	51 Neutral	$7.81B	-0.22	-40.01%	2.29%	21.48%	-2.11%

Aurobindo Pharma Ltd Corporate Events

CuraTeQ Biologics Gains EMA Positive Opinion for Dazublys®

CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for its trastuzumab biosimilar, Dazublys®, intended for treating HER2-positive breast cancers. This endorsement marks an important step for Aurobindo Pharma in strengthening its biosimilars portfolio, with expectations for European Commission approval by July, furthering its commitment to launching at least ten biosimilars by 2030 to enhance cancer care and address unmet patient needs.